Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 8-U.S. authorizes Moderna COVID-19 vaccine, elderly next in line for shots

Sat, 19th Dec 2020 00:44

(Adds comments from president-elect, infectious disease expert)

By Michael Erman

Dec 18 (Reuters) - Moderna Inc's coronavirus
vaccine on Friday became the second to receive emergency use
authorization (EUA) from the U.S. Food and Drug Administration,
welcome news to a nation with a staggering COVID-19 death toll
of over 307,000 lives lost.

Millions of doses of the Moderna vaccine are expected to be
added to the U.S. rollout, which began this week with healthcare
workers. Older people in long-term care facilities are next in
line for vaccines, with a U.S. Centers for Disease Control and
Prevention expert panel on Sunday set to recommend what groups
follow, as industries compete to have their workers given
precedence.

The FDA announced the authorization the day after the
agency's panel of outside experts endorsed its use and a week
after the FDA authorized a vaccine from Pfizer Inc and
German partner BioNTech SE.

The vaccine from Pfizer and BioNTech, based on similar
technology, has been put into the arms of thousands of U.S.
healthcare workers this week in a massive nationwide rollout.
Moderna injections are expected to begin in coming days for
adults 18 years old and up.

"With the availability of two vaccines now for the
prevention of COVID-19, the FDA has taken another crucial step
in the fight against this global pandemic that is causing vast
numbers of hospitalizations and deaths in the United States each
day,” FDA Commissioner Stephen M. Hahn, M.D, said in a
statement.

Moderna's shot is expected to be used in harder-to-reach
locations, such as rural hospitals. The vaccine needs to be
stored and shipped frozen, but does not require the ultra-cold
temperatures of the Pfizer/BioNTech shot.

The speed of vaccine development - less than a year from
when the first case of the new coronavirus was found in the
United States - is a stunning scientific success, although there
is some hesitancy among the public.

"It is my hope that all Americans will protect themselves by
getting vaccinated when the vaccine becomes available to them.
That is how our country will begin to heal and move forward,"
top U.S. infectious disease scientist Anthony Fauci said in a
statement.

Moderna said it intended to apply for full U.S. license in
2021.

The FDA decision marks the first regulatory authorization in
the world for Moderna's vaccine and validation of its messenger
RNA technology, shown to be nearly 95% effective with no serious
safety concerns. It came less than a year after the
first COVID-19 case was identified in the United States.

The vaccine, developed in partnership with the National
Institutes of Health, had relatively minor side effects
including pain around the injection site and swelling.

The biotech company has worked with the U.S. government to
prepare for the distribution of 5.9 million shots starting as
early as this weekend.

Once thawed, the Moderna vaccine can be kept at typical
refrigerator temperatures. It is administered in two shots 28
days apart.

Between the two vaccines, the United States is expecting 40
million doses before year end, enough to eventually vaccinate 20
million people, as both require two shots.

"Brighter days lie ahead," responded U.S. President-elect
Joe Biden, who plans to be vaccinated on Monday.

U.S. President Donald Trump on Twitter hailed the
authorization. "Congratulations, the Moderna vaccine is now
available!" he wrote. The vaccine must be transported to
hospitals and other centers before injections begin.

Moderna said it would deliver approximately 20 million doses
to the U.S. government this year and expected to have between
100 million and 125 million globally in the first quarter of
next year, with 85-100 million of those for the United States.

Moderna has deals with the U.S. government to provide a
total of 200 million doses by the end of June 2021. Other
vaccines still are in testing, including a one-shot injection
from Johnson & Johnson, and a two-shot course from AstraZeneca
and Oxford University.

U.S. hospitalizations and deaths have surged, driven by last
month's Thanksgiving holiday gatherings. Authorities have
renewed restrictions and shutdowns across the country.

Public health officials have warned infections from
Christmas and New Year's celebrations could exacerbate a crisis
that already threatens to overwhelm healthcare systems
nationwide.

Even with two highly effective vaccines, practices such as
social distancing and face covering will be needed for months
before enough people are inoculated to curb virus transmission
and eventually end the pandemic.

"With strong federal funding for swift vaccine rollout and
education, and by following the guidance of public health
experts to continue wearing masks and maintaining distance, we
can bring the end of this pandemic closer," Barbara Alexander,
head of the Infectious Diseases Society of America, said in a
statement.
(Reporting by Reporting by Kanishka Singh and Manojna
Maddipatla in Bengaluru, Michael Erman and Rebecca Spalding in
New York, Peter Henderson in Oakland and Julie Steenhuysen in
Chicago; Editing by Caroline Humer, Bill Berkrot and David
Gregorio)

More News
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.